Active Ingredient History

  • Now
Mecasermin rinfabate, also known as rhIGF-1/rhIGFBP-3, is a drug consisting of recombinant human insulin-like growth factor 1 (IGF-1) and recombinant human insulin-like growth factor binding protein-3 (IGFBP-3) which is used for the treatment of amyotrophic lateral sclerosis.   Wikipedia

More Chemistry
  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$3167.3600 - $4198.8000
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

cep-151 | human insulin-like growth factor i | igf1 | igf-1 | igfbp-3 | igf-i | igf-i-igfbp-3 complex | increlex | insulin growth factor 1 | insulin-like growth factor 1 | insulin-like growth factor-1 | insulin-like growth factor i | insulin like growth factor, type 1 | iplex | mecasermin | mecasermin recombinant | mecasermin rinfabate | mecasermin rinfabate [rdna origin] | mecasermin rinfabate recombinant | mechano growth factor | mescamerin recombinant | myotrophin | rhigf-i/rhigfbp-3 | somatokine | somatomedin c | somatomedin-c


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue